H.C. Wainwright lowered the firm’s price target on Zynex (ZYXI) to $8 from $15 and keeps a Buy rating on the shares. The company reported a top- and bottom-line miss in Q1, the analyst tells investors in a research note. The firm lowered 2025 revenue projection until the payor issue with Tricare is resolved.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYXI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue